Core Viewpoint - Ascendis Pharma has received FDA approval for a new treatment, positioning the company for potential growth as it nears a buy point in the stock market [1] Company Overview - Ascendis Pharma is a Denmark-based biotech company with three FDA-approved products developed using its TransCon technology platform, which aims to enhance treatment efficacy, tolerability, and convenience [1] - The company recently received FDA approval for Yuviwel, a weekly treatment for children with achondroplasia, a rare genetic condition affecting bone growth [1] - Other products include Skytrofa for pediatric growth hormone deficiency and Yorvipath for hypoparathyroidism, with a treatment for Turner syndrome currently in Phase 2 trials [1] Market Performance - Ascendis Pharma's stock reached an all-time high of $248.60 but retreated by 1.2% as the market fell [1] - The stock is currently trading around 2% below a buy point, with a relative strength line reaching a 52-week high [1] - As of December, 509 mutual funds owned shares of Ascendis, an increase from 493 in September, indicating growing institutional interest [1] Financial Performance - In the fourth quarter, Ascendis reported a loss of $0.65 per share on revenue of $290.7 million [1] - Analysts project the company will turn a profit of $0.40 per share in the first quarter, with earnings expected to increase to $0.88, $1.45, and $2.27 per share over the next three quarters [1] - Full-year 2027 profit forecasts from Wall Street estimate earnings of $12.34 per share, with a three-year sales growth rate of 122% [1]